CategorySurgical robots
Overview
Houston-based endoluminal robotic surgery company. CEO Eduardo Fonseca. Endoluminal Surgical (ELS) System — flexible robot for scar-free procedures through natural orifices. PARADIGM Trial: FDA-approved final stage (Jan 2026), 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA). First robotic ESD by gastroenterologist in IDE trial (Oct 2025). Series D-2 co-led by Crescent Enterprises + Dr. Fred Moll (Intuitive Surgical co-founder). NVIDIA IGX Thor integration for AI vision. $176M total raised.
Verified record
- Verified deployments
- 1 deployment on file
- Active incidents
- None on file
Key facts
Product
Trial
FDA Status
Total Fundingsee investors →
Partnership
Data & sources
Web sources
3
3 sources backing this record.View all →
Models (2)
View all models →Current platform
Endoluminal Surgical (ELS) System
Endoluminal Surgical (ELS) System is a surgical robot from EndoQuest Robotics, currently in pilot deployment.
Current platform
Endoluminal Robotic Surgical System
Endoluminal Robotic Surgical System is a surgical robot from EndoQuest Robotics, currently in pilot deployment.
EndoQuest Robotics on the deployment map
Where EndoQuest Robotics's robots are verified operating. Explore the deployment map by place and type.
Relationships
Current leadership (2)
- Eduardo Fonseca CEOreported, not verified
- Fred Moll Series D-2 Co-Lead Investorreported, not verified
Safety record
No incidents on record for EndoQuest Robotics.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Operated deployments (1)
- Endoluminal Robotic Surgical SystemDallas-Houston Corridor, Texas, USA
Operator customers (1)
- EndoQuest Robotics1 deployment
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJul 22, 2026
Added to the verified registry
Sources (3)
- https://www.massdevice.com/endoquest-gets-fda-green-light-to-initiate-final-stage-of-surgical-robot-trial/
- https://finance.yahoo.com/news/endoquest-robotics-secures-series-d-120000732.html
- https://www.businesswire.com/news/home/20260112765182/en/EndoQuest-to-Bring-AI-Powered-Vision-and-Precision-to-Endoluminal-Robotic-Surgery-with-NVIDIA-IGX-Thor
Common questions
- What is EndoQuest Robotics?
- Houston-based endoluminal robotic surgery company. CEO Eduardo Fonseca. Endoluminal Surgical (ELS) System — flexible robot for scar-free procedures through natural orifices. PARADIGM Trial: FDA-approved final stage (Jan 2026), 50 patients, 5 US centers (Brigham, Mayo, Cleveland Clinic, AdventHealth, HCA). First robotic ESD by gastroenterologist in IDE trial (Oct 2025). Series D-2 co-led by Crescent Enterprises + Dr. Fred Moll (Intuitive Surgical co-founder). NVIDIA IGX Thor integration for AI vision. $176M total raised.
- What does EndoQuest Robotics make?
- EndoQuest Robotics has 2 robot models on the DEPLOY registry: Endoluminal Surgical (ELS) System, Endoluminal Robotic Surgical System (EndoQuest Robotics builds physical robots).
- Who is the CEO of EndoQuest Robotics?
- Eduardo Fonseca is the ceo of EndoQuest Robotics, per the DEPLOY registry.
- Where is EndoQuest Robotics headquartered?
- EndoQuest Robotics is headquartered in Houston, TX.
- Where does EndoQuest Robotics operate robots?
- EndoQuest Robotics operates 1 verified deployment, including at Dallas-Houston Corridor, Texas, USA.
- Is EndoQuest Robotics a top robotics company?
- On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, EndoQuest Robotics ranks in roughly the top 46% of companies tracked by the registry.
- Is EndoQuest Robotics safe?
- EndoQuest Robotics has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 3 sources (no primary) · last reviewed 2026-07-22
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-07-22
Sources by quality tier
- 3
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for EndoQuest Robotics.Machine-readable surfaces
- Markdown mirror: /companies/endoquest.md
- RSS feed: /companies/endoquest/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/06e82f4d-e2d5-4a09-a089-c752f2f22056
- Revision history: /companies/endoquest/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Video
What is the big news with endoluminal surgical robots in 2026. How is endoscopy about to change? Steve Bell gives his predictions on the big themes we will see.
Episode breakdown: 00:00 Introduction to Robotics and EndoQuest 02:55 The Problem of Traditional Endoscopy 06:13 Efficiency and Learning Curves in Endoscopic P
Renowned Gi endoscopist Austin Chiang MD and robotics expert Steve Bell dive deeper into the merging worlds of endoluminal robotics and GI endoscopy. What are
Kurt discusses the rapid development of the EndoQuest platform, which is a flexible endoluminal robotic surgery system with the ability to perform scar-free sur
Reality vs attention
EndoQuest Robotics draws attention at the 5th percentile but verifies reality at the 5th percentile among surgical robots. Hype Gap +0.5, 14th widest among surgical robots.
6-month trend
Analysis
Clean safety record across 1 verified deployment. Deployment footprint remains limited relative to category peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 24, 2026